CTMX
CytomX Therapeutics Inc
2.60$
+0.8%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.8% | +55.8% | -39.4% | +33.1% | +13.9% | +33.7% | -63.4% | -68.0% | -88.9% | +1,447.2% | -86.2% | – | |
| – | -65.9% | -3.9% | -1.7% | – | – | – | – | – | – | -50.8% | – | – | |
| – | +6.6% | +55.8% | -39.4% | +33.1% | +13.9% | +33.7% | -63.4% | -68.0% | -88.9% | +1,409.4% | -85.8% | – | |
| – | +85.9% | +13.8% | +14.1% | -15.1% | -30.8% | +27.6% | -29.4% | +14.9% | +38.8% | -9.4% | -8.5% | – | |
| – | +14.9% | -0.9% | +8.3% | -5.3% | -29.3% | +67.6% | -29.8% | -2.9% | +14.5% | +45.3% | -28.9% | – | |
| – | +96.3% | +9.5% | +12.6% | -12.6% | -30.4% | +38.6% | -29.5% | +9.0% | +31.6% | +3.8% | -15.1% | – | |
| – | -105.5% | – | -172.5% | – | +330.0% | +28.0% | -105.7% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -67.2% | +626.1% | -146.8% | – | +226.7% | +24.5% | -100.4% | – | – | – | – | – | |
| – | -62.1% | -95.4% | +4.1% | +19.6% | +1.6% | +0.0% | +1.6% | -7.9% | -6.9% | +9.3% | +1.7% | – | |
| – | -72.0% | +1,547.7% | -147.4% | – | +229.1% | +24.6% | -100.7% | – | – | – | – | – | |
| – | -67.0% | +498.1% | -142.1% | – | +210.8% | +23.9% | -98.9% | -5,583.2% | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.